Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Novartis AG

SwitzerlandAdoptersAssignment FullData quality Medium

Key messagelimited AI Footprint

Novartis has published principles and a policy for the responsible use of artificial intelligence and describes a verifiable programme to protect its IT systems, but does not disclose who is responsible for AI at the top level or how individual AI applications are tested. Since March 2026 a class action has been pending in the US over the sharing of patient data via advertising tracking on product websites; no link to AI is alleged there.

Disclosure: the research was supported by an AI model made by Anthropic. Novartis AG is connected to Anthropic (e.g. as investor, partner, supplier, customer or through people). The assessment was therefore reviewed by people.

Opportunities

  • Safetysolid

    The cybersecurity disclosure in the 20-F for FY2025 documents a specific programme with a Chief Security Officer, a dedicated team, a 24/7 security operations centre, internal and external attack testing, alignment with NIST and ISO 27001 and escalation to the CEO and the board (S02).

    The cybersecurity disclosure in the 20-F for FY2025 documents a specific programme with a Chief Security Officer, a dedicated team, a 24/7 security operations centre, internal and external attack testing, alignment with NIST and ISO 27001 and escalation to the CEO and the board (S02). On the reliability and validation of AI systems there are only company statements, such as testing for hallucination and robustness and access limits for agents (S31, S33). Counter-evidence is the pending class action over tracking pixels on product websites (medium, without a link to AI) and a data breach at the service provider Lash Group in 2024 (S24, S25, S27). The pillar is therefore solid, but not very specific to AI itself.

Risks

  • Responsibilitylimited

    Novartis has published AI principles, a binding policy on the ethical use of data and technology and an AI Risk & Compliance Management Framework with four risk classes that also covers purchased AI (S10, S12, S33); however, these statements are policies and unverified company statements.

    Novartis has published AI principles, a binding policy on the ethical use of data and technology and an AI Risk & Compliance Management Framework with four risk classes that also covers purchased AI (S10, S12, S33); however, these statements are policies and unverified company statements. An explicit responsibility for AI at board or executive committee level is not documented: the nonfinancial report does not assign data, digital and AI to any committee or member of the executive committee (S06, S07). Only general accountability instruments are verifiably documented, such as the KPMG-assured figures on ethics training and SpeakUp (S06, S08), which have no link to AI.

  • Transparencylimited

    The policy requires users to be informed about the use of AI and its purpose (S12), and Novartis discloses AI principles, partnerships and areas of use (S10, S16, S35).

    The policy requires users to be informed about the use of AI and its purpose (S12), and Novartis discloses AI principles, partnerships and areas of use (S10, S16, S35). For none of its own systems (data42, AE Brain, study reports) are limits, error rates, labelling practice or model information published. Transparency therefore rests only on grade C evidence.

  • Risk area

    AI in clinical trials and drug safety

  • Risk area

    AI in regulatory and clinical study documents

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
43searches
41pages and documents read
11primary documents
2controversies checked
5open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Novartis AGOverall rating: limited

Novartis has published AI principles, a binding policy and a framework with risk classes, and describes a specific security programme. Who is responsible for AI at the top and how individual AI systems are tested is not documented.

Responsibility

40 %
limitedsolidstrong

A policy and risk classes exist, but no AI responsibility at the top is documented.

  • +Framework with four risk classes also covering purchased AI Source ↗
  • +Binding data and technology policy with a named owner unit Source ↗
  • +SpeakUp reporting channel with KPMG-assured figures Source ↗
  • –No AI responsibility documented on the board or executive committee Source ↗
  • –No metrics or external audit of the AI programme
All sources for this pillar (13)

Transparency

20 %
limitedsolidstrong

Principles and areas of use are disclosed, but not the limits of its own systems.

  • +Policy requires information on the use of AI Source ↗
  • +AI applications and partnerships described in reports Source ↗
  • –No limits or error rates of its own AI systems published
  • –No model or system documentation for data42 and AE Brain
All sources for this pillar (8)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
AI responsibility at the top

Assign AI to a board committee and an executive committee member and have the AI review figures externally assured.

2Safety
Document AI validation

Publish evidence of validation and monitoring of AI in trials, drug safety and manufacturing.

3Transparency
System information for its own AI

Disclose purpose, limits, error rates and data provenance for data42, AE Brain and other in-house systems.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Novartis AG is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
2 1 medium, 1 minor

No deduction for controversies.

Largest risk area
AI errors in trials and drug safety

Novartis uses AI for safety analyses, trial design and adverse event reports without publishing evidence of validation or monitoring.

How thoroughly assessed
33 Evidence

11 primary documents read, 43 searches.

Read the full reasoning and all sources
Novartis AG · Full reasoning

AI policy with risk classes, but no documented AI responsibility at the top

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Novartis has published principles, a policy and a framework with risk classes, but these are unverified company statements and are not assigned to any committee or executive committee member.

What is documented
  • The 2024 AI Risk & Compliance Management Framework distinguishes the classes low, medium, high and prohibited and also applies to jointly developed and purchased AI8 9
  • The owner of the policy on the ethical use of data and technology is the Data Privacy, Digital and AI Compliance unit5
  • According to an interview, deployment is preceded by an impact assessment and, for higher risks, an in-depth review6
  • The SpeakUp channel allows anonymous reports with protection from retaliation; the figures are subject to limited assurance by KPMG3 10
  • In the 20-F the implementation of AI in research is named as a separate risk factor7
The case against
Missing responsibility
  • The nonfinancial report does not assign data, digital and AI to any committee or member of the executive committee3 4
  • The Risk Committee was dissolved at the 2026 AGM; who has exercised oversight of cyber and AI since then is not documented2 1
No evidence of effectiveness
  • The number and results of AI risk reviews and a register of AI systems in use are not published
  • No external audit or certification of the AI programme was found
Sources for Responsibility (13)
  1. Novartis AG (SEC EDGAR, XBRL): Form 20-F FY2025, R8: Cybersecurity Risk Management and Strategy Disclosure (Item 16K) · 31 December 2025 · primary source
  2. Novartis AG (SEC EDGAR, Form 6-K Exhibit 99.1): Novartis Annual Report 2025 · 4 February 2026 · primary source
  3. Novartis AG: Report on Nonfinancial Matters 2025 · 31 December 2025 · primary source
  4. Novartis AG (SEC EDGAR, Form 6-K Exhibit 99.2): Report on Nonfinancial Matters 2025 (SEC filing version) · 4 February 2026 · primary source
  5. Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
  6. Fieldfisher: Interview with Simon Bristow, Global Data Privacy and AI Expert, Novartis · 3 November 2026 · secondary source
  7. Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  8. Novartis AG: Our commitment to ethical and responsible use of AI · 1 January 2024 · secondary source
  9. Novartis AG: Artificial intelligence · 3 November 2026 · secondary source
  10. Novartis AG: ESG Data Summary 2025 · 31 December 2025 · primary source
  11. Novartis AG: Code of Ethics · 3 November 2026 · secondary source
  12. Novartis AG: Novartis in Society Integrated Report 2024 · 31 December 2024 · secondary source
  13. Novartis US: Novartis US Invests in Data and AI Capabilities for 6,000 Employees · 16 September 2026 · secondary source

2 · Safety

solidWeight 40%

Novartis documents a specific cybersecurity programme in its 20-F, but on the testing of AI systems there are only company statements, and a class action over tracking on product websites is pending.

What is documented
  • A Chief Security Officer and a dedicated team under the CIO report figures to the executive committee; a security operations centre works around the clock4
  • Simulated attacks, external tests and recovery plans are described, aligned with NIST CSF and ISO 270014
  • The policy requires immediate reporting of incidents and data protection breaches6
  • According to an interview, models are tested for hallucination and robustness; InfoSec sets access limits for agents3
  • The 20-F names risks from AI-enhanced attacks and from AI service providers1
The case against
Missing evidence of AI testing
  • No evidence of validation and monitoring of AI in trials, drug safety and manufacturing was found
  • No ISO 27001 certification is stated, and AI-specific controls such as red-teaming are not described4
Data incidents
  • According to the lawsuit, tracking pixels on product websites passed diagnosis and prescription data to Google and Contentsquare without consent7 8 9
  • In 2024 data on participants in Novartis patient programmes was stolen at the service provider Lash Group10 11
Sources for Safety (12)
  1. Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  2. Novartis AG: Novartis Responsible Use of AI Systems · 1 October 2020 · secondary source
  3. McKinsey & Company: Novartis's Christian Diehl on scaling AI beyond the demo · 21 September 2026 · secondary source
  4. Novartis AG (SEC EDGAR, XBRL): Form 20-F FY2025, R8: Cybersecurity Risk Management and Strategy Disclosure (Item 16K) · 31 December 2025 · primary source
  5. Novartis AG: ESG index – Governance · 3 November 2026 · secondary source
  6. Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
  7. pharmaphorum: Patient sues Novartis, claiming data-tracking privacy breach · 25 March 2026 · secondary source
  8. Bloomberg Law: Novartis Sued Over Tracking Pixels on Drug-Discount Websites · 24 March 2026 · secondary source
  9. Fierce Pharma: Novartis sued by breast cancer patient over branded drug websites' data-sharing practices · 19 March 2026 · secondary source
  10. JD Supra: Novartis Patient Information Leaked in Lash Group Data Breach · 22 May 2024 · secondary source
  11. SC World: Nearly a dozen drug firms impacted by Cencora breach · 21 February 2024 · secondary source
  12. Board Cybersecurity (Incident Tracker): Novartis Pharmaceuticals Cybersecurity Incident · 22 May 2024 · secondary source

3 · Transparency

limitedWeight 20%

Novartis commits to informing people about the use of AI and describes areas of use, but discloses neither limits nor model information for its own systems such as data42 or AE Brain.

What is documented
  • The policy requires users to be informed about the use of AI and its purpose, and calls for representative training data2
  • Explainability and human oversight are named as risk areas of the framework7
  • Reports and announcements describe AI applications in research and development and partnerships such as the one with Isomorphic Labs4 5
The case against
No system information
  • For data42, AE Brain and automated study reports, neither limits, error rates nor model information are published
  • How patients and healthcare professionals are informed about the use of AI is not documented
  • There is only general information on consent and anonymisation of training data8
Sources for Transparency (8)
  1. Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
  2. Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
  3. Novartis AG: Novartis Responsible Use of AI Systems · 1 October 2020 · secondary source
  4. Novartis AG: Novartis in Society Integrated Report 2024 · 31 December 2024 · secondary source
  5. Pharma Focus Europe: Isomorphic Labs Announces Novartis Collaboration Expansion · 19 February 2025 · secondary source
  6. Novartis US: Novartis US Invests in Data and AI Capabilities for 6,000 Employees · 16 September 2026 · secondary source
  7. Novartis AG: Our commitment to ethical and responsible use of AI · 1 January 2024 · secondary source
  8. McKinsey & Company: Novartis's Christian Diehl on scaling AI beyond the demo · 21 September 2026 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: within the window there is no judgment, authority decision or fine on harm from Novartis's AI; the tracking lawsuit and the service provider incident have no documented link to AI.

5 · Controversies (2)

6 · What remains open

  • Board and executive committee responsibility for AI and cybersecurity after the Risk Committee was dissolved
  • Figures on the AI programme, such as the number of reviews, high-risk systems and prohibited applications
  • Evidence of validation and monitoring of AI in trials, drug safety and manufacturing
  • Status of and remedy in the tracking lawsuit
  • Governance and legal chapters of the 2025 20-F and annual report, which were truncated on retrieval

7 · How it was assessed

Cut-off date: 3 November 2026 · 43 searches, 41 fetches.

Primary documents read (11)
  • Form 20-F FY2025 (Risk Factors) and XBRL R8 (Item 16K), R28, R35
  • Annual Report 2025 (to p. 23)
  • Report on Nonfinancial Matters 2025 (novartis.com and SEC version)
  • ESG Data Summary 2025
  • Novartis in Society Integrated Report 2024
  • Interim Reports Q1 2026 and Q3 2026 (Form 6-K)
  • Ethical Use of Data and Technology Policy v2.0
  • Our commitment to ethical and responsible use of AI
  • Responsible Use of AI Systems (2020)
  • Code of Ethics
  • AGM 2026 Press Release

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next